LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 292

Search options

  1. Book: Advances in immuno-oncology

    Socinski, Mark A.

    immune checkpoint inhibitors in non-small cell lung cancer

    (Seminars in oncology ; vol 42, no 5, suppl 2 (October 2015))

    2015  

    Author's details Mark Socinski, MD, guest editor
    Series title Seminars in oncology ; vol 42, no 5, suppl 2 (October 2015)
    Collection
    Language English
    Size S28 Seiten, Illustrationen
    Publisher Saunders, an Imprint of Elsevier
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT018855046
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1348 -42,Suppl.2- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy.

    Leal, Ticiana / Socinski, Mark A

    Expert review of anticancer therapy

    2023  Volume 23, Issue 8, Page(s) 817–833

    Abstract: Introduction: Lung cancer is the second most common cancer in the world and the leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs), as monotherapy or in combination with platinum-based chemotherapy, have emerged as the ... ...

    Abstract Introduction: Lung cancer is the second most common cancer in the world and the leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs), as monotherapy or in combination with platinum-based chemotherapy, have emerged as the standard of care first-line treatment option for patients with advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Despite significant improvements in patient outcomes with these regimens, primary or acquired resistance is common and most patients develop disease progression, resulting in poor survival.
    Areas covered: We review the current treatments commonly used for NSCLC without AGAs in the first-line and subsequent settings and describe the unmet needs for these patients in the second-line setting, including a lack of standard definitions for primary and required resistance, and few effective treatment options for patients who develop progression of their disease on first-line therapy. We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.
    Expert opinion: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Immunotherapy/methods ; Treatment Outcome ; Genomics
    Language English
    Publishing date 2023-07-24
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2023.2235895
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5907: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Recent advances in taxanes for the first line treatment of advanced non-small cell lung cancer

    Socinski, Mark A. / Govindan, Ramaswamy / Spigel, David

    (Clinical advances in hematology & oncology ; 10,10, Suppl. 18)

    2012  

    Title variant Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer
    Author's details moderator Mark A. Socinski ; discussants Ramaswamy Govindan ; David Spigel
    Series title Clinical advances in hematology & oncology ; 10,10, Suppl. 18
    Collection
    Language English
    Size 15 S. : graph. Darst.
    Publisher Millennium Med. Publ
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT017478484
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6505 -10,Suppl.18- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine.

    Villaruz, Liza C / Socinski, Mark A / Weiss, Jared

    Frontiers in oncology

    2023  Volume 13, Page(s) 1124167

    Abstract: Major advances in the diagnosis and treatment of non-small cell lung cancer (NSCLC) have resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the forefront of precision medicine. Current guidelines recommend upfront ... ...

    Abstract Major advances in the diagnosis and treatment of non-small cell lung cancer (NSCLC) have resulted in a sharp decline in associated mortality rates, thereby propelling NSCLC to the forefront of precision medicine. Current guidelines recommend upfront comprehensive molecular testing for all known and actionable driver alterations/biomarkers (
    Language English
    Publishing date 2023-02-01
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1124167
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: How I treat stage IV non-small cell lung cancer in the absence of any actionable oncogenic driver.

    Socinski, Mark A

    Clinical advances in hematology & oncology : H&O

    2017  Volume 15, Issue 10, Page(s) 759–765

    MeSH term(s) Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/therapy ; Humans ; Immunotherapy/methods ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Lung Neoplasms/therapy ; Neoplasm Staging ; Oncogenes
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2017-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: GEMSTONE-302: "If you keep doing the same thing you get the same result".

    Guo, Mengni / Liu, Jieying / Mekhail, Tarek / Socinski, Mark A

    Chinese clinical oncology

    2022  Volume 11, Issue 6, Page(s) 48

    MeSH term(s) Humans ; Lung Neoplasms ; Immunotherapy ; B7-H1 Antigen
    Chemical Substances B7-H1 Antigen
    Language English
    Publishing date 2022-11-15
    Publishing country China
    Document type Journal Article
    ZDB-ID 2828547-5
    ISSN 2304-3873 ; 2304-3873
    ISSN (online) 2304-3873
    ISSN 2304-3873
    DOI 10.21037/cco-22-103
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: MET

    Socinski, Mark A / Pennell, Nathan A / Davies, Kurtis D

    JCO precision oncology

    2021  Volume 5

    MeSH term(s) Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/genetics ; Exons/genetics ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/genetics ; Mutation ; Proto-Oncogene Proteins c-met/genetics
    Chemical Substances MET protein, human (EC 2.7.10.1) ; Proto-Oncogene Proteins c-met (EC 2.7.10.1)
    Language English
    Publishing date 2021-04-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.20.00516
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.

    Li, Lee X / Cappuzzo, Federico / Matos, Ignacio / Socinski, Mark A / Hopkins, Ashley M / Sorich, Michael J

    The oncologist

    2023  Volume 28, Issue 4, Page(s) e205–e211

    Abstract: ... 3129) experienced hyperprogression. Hyperprogression risk was markedly lower with first-line ... presents first evidence for a markedly lower hyperprogression risk in advanced NSCLC patients treated ... between groups. Landmark Cox proportional-hazard regression was used to evaluate the association between ...

    Abstract Background: Monotherapy immune checkpoint inhibitor (ICI) used in second- or later-line settings has been reported to induce hyperprogression. This study evaluated hyperprogression risk with ICI (atezolizumab) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer (NSCLC), and provides insights into hyperprogression risk with contemporary first-line ICI treatment.
    Methods: Hyperprogression was identified using Response Evaluation Criteria in Solid Tumours (RECIST)-based criteria in a dataset of pooled individual-participant level data from BIRCH, FIR, IMpower130, IMpower131, IMpower150, OAK, and POPLAR trials. Odds ratios were computed to compare hyperprogression risks between groups. Landmark Cox proportional-hazard regression was used to evaluate the association between hyperprogression and progression-free survival/overall survival. Secondarily, putative risk factors for hyperprogression among second- or later-line atezolizumab-treated patients were evaluated using univariate logistic regression models.
    Results: Of the included 4644 patients, 119 of the atezolizumab-treated patients (n = 3129) experienced hyperprogression. Hyperprogression risk was markedly lower with first-line atezolizumab-either chemoimmunotherapy or monotherapy-compared to second/later-line atezolizumab monotherapy (0.7% vs. 8.8%, OR = 0.07, 95% CI, 0.04-0.13). Further, there was no statistically significant difference in hyperprogression risk with first-line atezolizumab-chemoimmunotherapy versus chemotherapy alone (0.6% vs. 1.0%, OR = 0.55, 95% CI, 0.22-1.36). Sensitivity analyses using an extended RECIST-based criteria including early death supported these findings. Hyperprogression was associated with worsened overall survival (HR = 3.4, 95% CI, 2.7-4.2, P < .001); elevated neutrophil-to-lymphocyte ratio was the strongest risk factor for hyperprogression (C-statistic = 0.62, P < .001).
    Conclusions: This study presents first evidence for a markedly lower hyperprogression risk in advanced NSCLC patients treated with first-line ICI, particularly with chemoimmunotherapy, as compared to second- or later-line ICI treatment.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease Progression ; Immune Checkpoint Inhibitors/adverse effects ; Lung Neoplasms/pathology ; Progression-Free Survival
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-03-11
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1093/oncolo/oyad043
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction.

    Socinski, Mark A

    Seminars in oncology

    2015  Volume 42 Suppl 2, Page(s) S1–2

    MeSH term(s) Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/immunology ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/therapy ; Humans ; Immunotherapy/methods ; Immunotherapy/trends ; Lung Neoplasms/immunology ; Lung Neoplasms/therapy ; Lymphocyte Activation/immunology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Signal Transduction/immunology ; T-Lymphocytes/immunology
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; nivolumab (31YO63LBSN)
    Language English
    Publishing date 2015-10
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 189220-4
    ISSN 1532-8708 ; 0093-7754
    ISSN (online) 1532-8708
    ISSN 0093-7754
    DOI 10.1053/j.seminoncol.2015.09.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1348: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.

    Socinski, Mark A

    Seminars in oncology

    2015  Volume 42 Suppl 2, Page(s) S19–28

    Abstract: Immunotherapy provides unique challenges in the clinic, as nivolumab is a first-in-class agent for non-small cell lung cancer (NSCLC). Unlike other NSCLC therapies, immunotherapy cannot currently be selected based on a patient's clinical characteristics ... ...

    Abstract Immunotherapy provides unique challenges in the clinic, as nivolumab is a first-in-class agent for non-small cell lung cancer (NSCLC). Unlike other NSCLC therapies, immunotherapy cannot currently be selected based on a patient's clinical characteristics or a tumor's molecular characteristics, although some evidence suggests that programmed death ligand 1 (PD-L1) may be useful as a molecular biomarker in the future. Histology is currently important to the use of nivolumab because it is only approved in squamous cell NSCLC. However, recent evidence shows a similar survival benefit of nivolumab in nonsquamous disease, so histology will likely not be a distinguishing factor in the future. It has been discovered that immunotherapy often has delayed response kinetics, leading to the development of immune-related response criteria (irRC) in 2009. The irRC have distinguishing characteristics from traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria that prevent physicians from prematurely discontinuing immunotherapy. In addition to these differences in response criteria, the safety profiles of immunotherapeutic agents are distinct from other NSCLC therapies. The toxicities frequently associated with immunotherapies are unlike common chemotherapy toxicities because they are autoimmune in nature. Thus, physicians are presented with the challenge of appropriately identifying and managing these unfamiliar immune-related adverse events.
    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/immunology ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/therapy ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Lung Neoplasms/genetics ; Lung Neoplasms/immunology ; Lung Neoplasms/therapy ; Pharmacogenetics/methods ; Practice Guidelines as Topic ; Precision Medicine/methods
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; nivolumab (31YO63LBSN)
    Language English
    Publishing date 2015-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 189220-4
    ISSN 1532-8708 ; 0093-7754
    ISSN (online) 1532-8708
    ISSN 0093-7754
    DOI 10.1053/j.seminoncol.2015.09.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1348: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top